10x Genomics, Inc. — Director's Dealing 2021

Jul 26, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2021-07-23

Reporting Person: Kosaraju Sridhar (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-07-23	Class A Common Stock	S	459	$182.3188	Disposed	11541	Indirect
2021-07-23	Class A Common Stock	S	400	$183.0748	Disposed	11141	Indirect
2021-07-23	Class A Common Stock	S	400	$184.4273	Disposed	10741	Indirect
2021-07-23	Class A Common Stock	S	241	$185.9551	Disposed	10500	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Class A Common Stock	3458	Direct

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Kosaraju Family Trust dated June 21, 2014, of which the Reporting Person is trustee (the "Kosaraju Family Trust").

F2: This transaction was executed in multiple trades at prices ranging from $181.69 to $182.67. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3: These shares are held by the Kosaraju Family Trust.

F4: This transaction was executed in multiple trades at prices ranging from $182.89 to $183.525. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F5: This transaction was executed in multiple trades at prices ranging from $184.07 to $184.78. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F6: This transaction was executed in multiple trades at prices ranging from $185.39 to $186.31. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.